CMP
UTHR icon

Coston McIsaac & Partners’s United Therapeutics UTHR Stock Holding History

Coston McIsaac & Partners’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-30
Closed -$17K – 930
2026
Q1 		$17K Buy
+30
New +$14.9K ﹤0.01% 499
2023
Q2 		– Sell
-11
Closed -$2K – 851
2023
Q1 		$2K Buy
+11
New +$2.71K ﹤0.01% 719

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Coston McIsaac & Partners's UTHR Position: Q2 2026 in Review

Coston McIsaac & Partners sold out of United Therapeutics (UTHR) in Q2 2026, closing a stake of 30 shares — an estimated $17K sold.

Coston McIsaac & Partners first reported a position in UTHR in Q1 2023 and held it in 2 quarters. The position peaked at $17K in Q1 2026. 882 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Coston McIsaac & Partners reported no remaining United Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Coston McIsaac & Partners sold 30 United Therapeutics shares in Q2 2026, an estimated $17K.
  • Coston McIsaac & Partners first reported a position in United Therapeutics in Q1 2023 and held it in 2 quarters.
  • Coston McIsaac & Partners's United Therapeutics position peaked at $17K in Q1 2026.
  • 882 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Coston McIsaac & Partners's 13F filing for Q2 2026, filed 12 Aug 2026.